# Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

> **NCT02873338** · PHASE2 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 75 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Dociparstat sodium
- **DRUG:** Idarubicin
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT02873338
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02873338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02873338, "Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02873338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*